Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD.

Gastroenterology. 2010 Mar;138(3):958-68. doi: 10.1053/j.gastro.2009.11.005. Epub 2009 Nov 13.

2.

A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.

Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, Stein U, Fichtner I, Schlag PM, Birchmeier W.

Gastroenterology. 2009 Jul;137(1):165-75. doi: 10.1053/j.gastro.2009.03.041. Epub 2009 Mar 26.

PMID:
19328798
3.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
4.

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.

JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.

PMID:
26502222
5.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

6.

Prognostic implications of serum microRNA-21 in colorectal cancer.

Menéndez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menéndez JM, Rodríguez-Montes JA.

J Surg Oncol. 2013 Nov;108(6):369-73. doi: 10.1002/jso.23415. Epub 2013 Aug 23.

PMID:
23970420
7.

Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.

Reimers MS, Kuppen PJ, Lee M, Lopatin M, Tezcan H, Putter H, Clark-Langone K, Liefers GJ, Shak S, van de Velde CJ.

J Natl Cancer Inst. 2014 Sep 26;106(11). pii: dju269. doi: 10.1093/jnci/dju269. Print 2014 Nov.

PMID:
25261968
8.

Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.

Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C.

World J Gastroenterol. 2015 Jan 21;21(3):926-34. doi: 10.3748/wjg.v21.i3.926.

9.

Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.

Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS.

Int J Colorectal Dis. 2009 Aug;24(8):875-84. doi: 10.1007/s00384-009-0725-z. Epub 2009 May 7.

PMID:
19421758
10.

Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas.

Xue G, Hao LQ, Ding FX, Mei Q, Huang JJ, Fu CG, Yan HL, Sun SH.

J Clin Gastroenterol. 2009 Oct;43(9):831-7. doi: 10.1097/MCG.0b013e31819cc731.

PMID:
19461527
11.

ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.

Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA.

Gut. 2012 Nov;61(11):1560-7. Epub 2012 Jan 2.

PMID:
22213796
12.

Gene expression profiles in esophageal adenocarcinoma predict survival after resection.

Pennathur A, Xi L, Litle VR, Gooding WE, Krasinskas A, Landreneau RJ, Godfrey TE, Luketich JD.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):505-12; discussion 512-3. doi: 10.1016/j.jtcvs.2012.10.031.

13.

A novel data-driven prognostic model for staging of colorectal cancer.

Manilich EA, Kiran RP, Radivoyevitch T, Lavery I, Fazio VW, Remzi FH.

J Am Coll Surg. 2011 Nov;213(5):579-588, 588.e1-2. doi: 10.1016/j.jamcollsurg.2011.08.006. Epub 2011 Sep 16.

PMID:
21925905
14.

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.

Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL.

Breast Cancer Res Treat. 2010 Oct;123(3):691-9. doi: 10.1007/s10549-009-0664-y. Epub 2009 Dec 6.

15.

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D.

J Clin Oncol. 2004 May 1;22(9):1564-71. Epub 2004 Mar 29.

PMID:
15051756
16.

Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.

Di Narzo AF, Tejpar S, Rossi S, Yan P, Popovici V, Wirapati P, Budinska E, Xie T, Estrella H, Pavlicek A, Mao M, Martin E, Scott W, Bosman FT, Roth A, Delorenzi M.

J Natl Cancer Inst. 2014 Sep 22;106(10). pii: dju247. doi: 10.1093/jnci/dju247. Print 2014 Oct.

PMID:
25246611
17.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ.

Clin Cancer Res. 2016 Feb 1;22(3):734-45. doi: 10.1158/1078-0432.CCR-15-0143. Epub 2015 Oct 7.

18.

Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.

He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ, Xie D.

Oncotarget. 2015 Oct 13;6(31):31181-90. doi: 10.18632/oncotarget.5070.

19.

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr.

Cancer Res. 1998 Mar 15;58(6):1149-58.

20.

Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.

Noske A, Lipka S, Budczies J, Müller K, Loddenkemper C, Buhr HJ, Kruschewski M.

Oncol Rep. 2009 Jul;22(1):3-9.

PMID:
19513497

Supplemental Content

Support Center